## Clinical Presentation Analysis The patient presents with: - **Fever + headache + myalgia + rash:** Classic dengue triad on day 4 of illness - **Bleeding manifestations:** Gum bleeding + petechiae on day 4 (critical phase) - **Thrombocytopenia:** 45,000/μL (moderate; <100,000 is diagnostic criterion) - **NS1 antigen positive:** Confirms dengue (detectable days 1–5 of illness) - **No prior dengue:** Primary infection (higher risk of severe dengue) ## NVBDCP Dengue Management Protocol **Key Point:** NVBDCP classifies dengue into three categories: dengue without warning signs, dengue with warning signs (DWS), and severe dengue (dengue hemorrhagic fever/DHF). This patient is in the **critical phase** (day 4) with warning signs (bleeding, thrombocytopenia <100,000). ```mermaid flowchart TD A[Dengue confirmed: NS1+]:::outcome --> B{Clinical features?}:::decision B -->|Fever only, no bleeding| C[Dengue without warning signs]:::outcome B -->|Fever + bleeding/thrombocytopenia| D[Dengue with warning signs]:::outcome C --> E[Outpatient: Oral fluids<br/>Paracetamol, avoid NSAIDs]:::action D --> F[Admit: IV access<br/>Isotonic crystalloid]:::action F --> G[Monitor: Vital signs<br/>Urine output, Hct, platelets]:::action B -->|Shock, severe bleeding| H[Severe dengue/DHF]:::urgent H --> I[IV fluids 1.5x maintenance<br/>Transfuse if Hct >20% rise]:::urgent G --> J{Hemoconcentration?}:::decision J -->|Yes| K[Reduce fluids, monitor<br/>for fluid overload]:::action J -->|No| L[Continue monitoring<br/>through critical phase]:::action ``` ## Why IV Fluids + Monitoring (Option 2) is Correct **High-Yield:** NVBDCP and WHO dengue management emphasizes **fluid therapy and supportive care** as the cornerstone of treatment: 1. **IV Access & Isotonic Crystalloid:** Establish IV access immediately in all dengue with warning signs. Use normal saline or Ringer's lactate at 1–1.5 mL/kg/hr (adjusted based on urine output and vital signs). 2. **Monitoring for Warning Signs:** The critical phase (days 3–5) is when plasma leakage peaks. Monitor for: - Persistent vomiting - Severe abdominal pain - Lethargy or restlessness - Liver enlargement >2 cm - Rapid drop in platelet count - Rising hematocrit (>20% increase from baseline) 3. **Transfusion Criteria:** Platelets and RBCs are transfused only if: - **Spontaneous bleeding** (not just low count) - **Hematocrit rise >20%** (indicates plasma leakage; fluid overload risk) - Platelet transfusion is **NOT** prophylactic; it is given only if active bleeding and count <20,000/μL **Clinical Pearl:** The key to dengue management is **judicious fluid therapy**. Over-transfusion and excessive fluids cause dengue shock syndrome and pulmonary edema. Platelet count alone does NOT dictate transfusion; clinical bleeding does. **Mnemonic:** **FLAW** — **F**luids (isotonic crystalloid), **L**aboratory monitoring (Hct, platelets), **A**void NSAIDs/aspirin, **W**arning signs vigilance. ## Rationale Against Other Options | Option | Why Wrong | |--------|----------| | Ribavirin (Option 0) | Ribavirin is an antiviral for viral hemorrhagic fevers (Lassa, Crimean-Congo). Dengue is RNA virus but has no specific antiviral; ribavirin is not indicated and adds toxicity. | | Prophylactic platelet transfusion + steroids (Option 1) | Platelet transfusion is NOT prophylactic in dengue; it is given only for spontaneous bleeding. Corticosteroids are contraindicated in dengue (increase bleeding risk, no mortality benefit). | | Bone marrow aspiration + RBC transfusion (Option 3) | Bone marrow aspiration is not indicated in dengue (diagnosis is serological). RBC transfusion is given only if Hct rises >20% from baseline (plasma leakage), not empirically. |
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.